Biotechnology - Anti-virals, Vaccines


Current filters:


Popular Filters

US declaration under PREP Act to support Ebola vaccines development


US Health and Human Services Secretary Sylvia Burwell yesterday announced a declaration under the Public…

Anti-viralsBavarian NordicBiotechnologyGlaxoSmithKlineJanssenJohnson & JohnsonLegalNewLink GeneticsResearchTropical diseasesUSAVaccines

“Overwhelming approval” in store for Heplisav if Dynavax delivers sufficient safety data, says analyst

“Overwhelming approval” in store for Heplisav if Dynavax delivers sufficient safety data, says analyst


Despite citing the need for further safety studies, both US and EU regulators have lauded the immunogenicity…

Anti-viralsBiotechnologyDynavax TechnologiesHeplisavRegulationResearchVaccines

Dynavax withdraws European MAA for Heplisav


US biotech firm Dynavax Technologies says it has withdrawn the European Marketing Authorization Application…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Creation of ABIVAX - a leader in therapeutic vaccines - in a Cuban collaboration


French venture capital firm Truffle Capital has announced the creation of Paris-based ABIVAX in collaboration…


Vivaldi Biosciences acquires clinical stage influenza vaccine assets


Privately-held US biotech firm Vivaldi Biosciences has acquired from Baxter Healthcare R&D assets, including…

Anti-viralsBaxter HealthcareBaxter InternationalBiotechnologyMergers & AcquisitionsVaccinesVivaldi Biosciences

Valneva licenses EB66 to IAVI for preventive HIV vaccine


Biotech firm Valneva says that it has licensed the use of its EB66 cell line to the International AIDS…


Immune Design and Medicago link up to develop flu vaccines


Privately-held US biotech firm Immune Design and Medicago (TSX: MDG), a Canadian biopharmaceutical company…

Anti-viralsBiotechnologyImmune DesignLicensingMedicagoVaccines

Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine


US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst


While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative…

Anti-viralsBiotechnologyFinancialHVTN 505PharmaceuticalResearchVaccines

FDA delays approval of Dynavax' Heplisav, issuing CRL


Dynavax Technologies ( Nasdaq: DVAX) saw its shares plunge as much as 38% to $1.84 in pre-market trading…

Anti-viralsBiotechnologyDynavax TechnologiesHeplisavNorth AmericaRegulationVaccines

Generex highlights pipeline potential of Antigen Express subsidiary


Canada-based Generex Biotechnology (OTC Bulletin Board: GNBT) last week provided an overview of the current…

AE37Anti-viralsAntigen ExpressBiotechnologyGenerex BiotechnologyOncologyPharmaceuticalResearchVaccines

FDA approves Protein Sciences egg-free flu vaccine Flublok; and Octapharma's Octaplas


The US Food and Drug Administration revealed it has approved privately-held US biotech firm Protein Sciences…

Anti-viralsBiotechnologyFlublokMergers & AcquisitionsNorth AmericaOctapharmaOctaplasPanblokPharmaceuticalProtein Sciences CorpRegulationVaccines

EMA accepts Dynavax' filing for hep B drug Heplisav


US biotech firm Dynavax Technologies (Nasdaq: DVAX) revealed yesterday that the European Medicines Agency…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Crucell and Scripps Research discover broad-spectrum antibodies against influenza B


In what is described as a landmark discovery, researchers from Crucell Holland, which became wholly-owned…

Anti-viralsBiotechnologyCrucellJohnson & JohnsonPharmaceuticalResearchVaccines

Silencing investor concerns? Alnylam achieves RNAi milestone


US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone…

Alnylam PharmaceuticalsAnti-viralsBiotechnologyFinancialGlaxoSmithKlineLicensingProductionVaccines

Back to top